Outlook Therapeutics is trading at $0.55, up 5.06%, with biotech-sector strength the clearest available context, not a confirmed company-specific catalyst.
- No company-specific announcement for October 21 was identified; its latest listed press release is dated October 9.
- Biotech ETF XBI is up 2.10%; sector gains are supported by dealmaking and clinical-trial news.
- Live trading volume was not provided.